Incidence rates of childhood asthma with recurrent exacerbations in the US Environmental influences on Child Health Outcomes (ECHO) program
- PMID: 36972767
- PMCID: PMC10330473
- DOI: 10.1016/j.jaci.2023.03.016
Incidence rates of childhood asthma with recurrent exacerbations in the US Environmental influences on Child Health Outcomes (ECHO) program
Abstract
Background: Descriptive epidemiological data on incidence rates (IRs) of asthma with recurrent exacerbations (ARE) are sparse.
Objectives: This study hypothesized that IRs for ARE would vary by time, geography, age, and race and ethnicity, irrespective of parental asthma history.
Methods: The investigators leveraged data from 17,246 children born after 1990 enrolled in 59 US with 1 Puerto Rican cohort in the Environmental Influences on Child Health Outcomes (ECHO) consortium to estimate IRs for ARE.
Results: The overall crude IR for ARE was 6.07 per 1000 person-years (95% CI: 5.63-6.51) and was highest for children aged 2-4 years, for Hispanic Black and non-Hispanic Black children, and for those with a parental history of asthma. ARE IRs were higher for 2- to 4-year-olds in each race and ethnicity category and for both sexes. Multivariable analysis confirmed higher adjusted ARE IRs (aIRRs) for children born 2000-2009 compared with those born 1990-1999 and 2010-2017, 2-4 versus 10-19 years old (aIRR = 15.36; 95% CI: 12.09-19.52), and for males versus females (aIRR = 1.34; 95% CI 1.16-1.55). Black children (non-Hispanic and Hispanic) had higher rates than non-Hispanic White children (aIRR = 2.51; 95% CI 2.10-2.99; and aIRR = 2.04; 95% CI: 1.22-3.39, respectively). Children born in the Midwest, Northeast and South had higher rates than those born in the West (P < .01 for each comparison). Children with a parental history of asthma had rates nearly 3 times higher than those without such history (aIRR = 2.90; 95% CI: 2.43-3.46).
Conclusions: Factors associated with time, geography, age, race and ethnicity, sex, and parental history appear to influence the inception of ARE among children and adolescents.
Keywords: Asthma; environmental and social determinants of asthma; incidence rates; recurrent exacerbations.
Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest:
Carlos A. Camargo, Jr. reports AstraZeneca (Scientific Advisory Board in 2020); Sanofi Genzyme (Scientific Advisory Board in 2021). José F. Cordero is a consultant to Sanofi Pasteur specifically about dengue vaccine development. James E. Gern has received consulting fees from AstraZeneca and Meissa Vaccines, Inc, and has stock options in Meissa Vaccines, Inc. Tina Hartert serves on vaccine DSMB and advisory panels for Pfizer and Sanofi (without funding). Daniel J. Jackson has funding from GlaxoSmithKline and Regeneron, personal fees for DSMB from Pfizer, and personal fees for consulting from AstraZeneca, Avillion, GlaxoSmithKline, Sanofi, Regeneron. All other authors (Rachel L. Miller, Holly Schuh, Aruna Chandran, Izzuddin M. Aris, Casper Bendixsen, Jeffrey Blossom, Carrie Breton, Glorisa Canino, Kecia N. Carroll, Sarah Commodore, Dana M. Dabelea, Assiamira Ferrara, Rebecca C. Fry, Jody M. Ganiban, Frank D. Gilliland, Diane R. Gold, Rima Habre, Marion E. Hare, Robyn N. Harte, Tina Hartert, Kohei Hasegawa, Gurjit K. Khurana Hershey, Daniel J. Jackson, Christine Joseph, Jean M. Kerver, Haejin Kim, Augusto A. Litonjua, Carmen J. Marsit, Cindy McEvoy, Eneida A. Mendonça, Paul E. Moore, Flory L. Nkoy, Thomas G. O’Connor, Emily Oken, Dennis Ownby, Matthew Perzanowski, Katherine Rivera-Spoljaric, Patrick H. Ryan, Anne Marie Singh, Joseph B. Stanford, Rosalind J. Wright, Robert O. Wright, Antonella Zanobetti, Edward Zoratti and Christine C. Johnson) have nothing to disclose.
Figures
References
-
- Federico MJ, Denlinger LC, Corren J, Szefler SJ, Fuhlbrigge AL. Exacerbation-prone asthma: a biological phenotype or a social construct. J Allergy Clin Immunol Pract 2021; 9:2627–34. - PubMed
-
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343–73. - PubMed
Publication types
MeSH terms
Grants and funding
- UH3 OD023332/OD/NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- U2C OD023375/OD/NIH HHS/United States
- UG3 OD023320/OD/NIH HHS/United States
- UH3 OD023271/OD/NIH HHS/United States
- UH3 OD023348/OD/NIH HHS/United States
- UH3 OD023248/OD/NIH HHS/United States
- UH3 OD023287/OD/NIH HHS/United States
- U24 OD023319/OD/NIH HHS/United States
- UH3 OD023347/OD/NIH HHS/United States
- R01 HL132338/HL/NHLBI NIH HHS/United States
- UH3 OD023288/OD/NIH HHS/United States
- UH3 OD023342/OD/NIH HHS/United States
- UH3 OD023365/OD/NIH HHS/United States
- UH3 OD023268/OD/NIH HHS/United States
- U24 OD023382/OD/NIH HHS/United States
- UH3 OD023313/OD/NIH HHS/United States
- UH3 OD023289/OD/NIH HHS/United States
- UH3 OD023249/OD/NIH HHS/United States
- UH3 OD023389/OD/NIH HHS/United States
- UH3 OD023290/OD/NIH HHS/United States
- UH3 OD023285/OD/NIH HHS/United States
- UG3 OD035517/OD/NIH HHS/United States
- UH3 OD023275/OD/NIH HHS/United States
- P30 ES001247/ES/NIEHS NIH HHS/United States
- UH3 OD023318/OD/NIH HHS/United States
- UL1 TR002538/TR/NCATS NIH HHS/United States
- KL2 TR001065/TR/NCATS NIH HHS/United States
- UH3 OD023286/OD/NIH HHS/United States
- UG3 OD023337/OD/NIH HHS/United States
- UH3 OD023282/OD/NIH HHS/United States
- UG3 OD023271/OD/NIH HHS/United States
- UH3 OD023253/OD/NIH HHS/United States
- UH3 OD023272/OD/NIH HHS/United States
- UL1 TR004419/TR/NCATS NIH HHS/United States
- UG3 OD023282/OD/NIH HHS/United States
- UH3 OD023251/OD/NIH HHS/United States
- UH3 OD023279/OD/NIH HHS/United States
- R01 HL109977/HL/NHLBI NIH HHS/United States
- UG3 OD023253/OD/NIH HHS/United States
- U19 AI095227/AI/NIAID NIH HHS/United States
- R01 HL105447/HL/NHLBI NIH HHS/United States
- UH3 OD023244/OD/NIH HHS/United States
- UH3 OD023320/OD/NIH HHS/United States
- UG3 OD023285/OD/NIH HHS/United States
- UH3 OD023337/OD/NIH HHS/United States
- UG3 OD023318/OD/NIH HHS/United States
- UG3 OD023249/OD/NIH HHS/United States
- P20 GM104416/GM/NIGMS NIH HHS/United States
- UG3 OD023290/OD/NIH HHS/United States
- UG3 OD035516/OD/NIH HHS/United States
- UH3 OD023328/OD/NIH HHS/United States
